Will enlighten on the relevance of FDCs vis-à-vis the global practices
The Indian Drug Manufacturers’ Association (IDMA) in collaboration with CIPI & FOPE is organising a seminar on “FDCs: the Way Forward” in Mumbai on April 26, 2014.
For the pharma industry, FDCs are a vital contributor to overall business and business growth. The SLA-approved FDCs have been dominating the Indian pharma space and have been well accepted by the medical professionals as well. However, the recent requirements spelt out by the DCGI office have played the spoilsport for the pharma industry in the country.
The seminar is intended to enlighten on the relevance of FDCs vis-à-vis the global practices, in the light of patients’ acceptability and understand whether there are any hurdles (real or virtual) faced by medical professionals in prescribing the same.
Drugs Controller General of India (DCGI) Dr GN Singh will be the chief guest in the seminar. Dr VG Somani, Joint Drugs Controller (India) – CDSCO(Delhi), will be the guest of honour, while Dr K Bangarurajan, Deputy Drugs Controller (India) – CDSCO West Zone (Mumbai) will be the special guest of the seminar.
The seminar will focus on a lot of pertinent issues such as how India is leading the world when it comes to FDCs, the divide between academia and private clinicians, the role of MSME’s as well as establishing guidelines for rationalising. A panel discussion on whether FDCs are a doctors delight or a clinicians dilemma will also be a held.
EH News Bureau